NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









STORM Therapeutics

STORM Therapeutics

Private
CambridgeHealthcare & Life Scienceshttps://www.stormtherapeutics.com/

Last Round

Series C

Apr 16, 2026

Est. Valuation

$50.5M

Total Funding Raised

$126.42M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

STORM Therapeutics is a biotechnology company that develops small molecule therapies targeting RNA modifying enzymes for the treatment of cancer and other immune diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

RNA-modifying enzymessmall molecule inhibitorsRMEsMETTL3 inhibitorRNA epigeneticscancer immunotherapydrug discovery platformfirst-in-class therapiesoncology therapiesRNA therapeuticssolid tumorsADAR1 inhibitorepitranscriptomicsclinical stage biotechundruggable targets

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

STORM Therapeutics Comps

Public and private peers based on sector, stage, and business model.

STORM Therapeutics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

STORM Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CApr 16, 2026
Series BDec 14, 2022
GrantMay 3, 2022
Series A ExtensionMay 20, 2019
GrantSep 3, 2018
Series A Extension
Jan 8, 2018

STORM Therapeutics Investors

Notable investors and investment history

STORM Therapeutics investors
InvestorRounds
Innovate UKGrant
IP GroupSeries B, Series A Extension, Series C
Seroba Life SciencesSeries B, Series A Extension
Taiho VenturesSeries A Extension, Series C, Series B
M VenturesSeries A Extension, Series C, Series A, Series B
UKRI Innovate UKGrant
Merck KGaASeries B, Series A Extension, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 16, 2026

    $56M round completed.

  • Feb 12, 2026

    Collaborating with Sygnature Discovery on DHX9 inhibitor program.

STORM Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

STORM Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about STORM Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge
Employee Range14
Year Founded2015
Last FundingApr 16, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.